.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: RE29618

« Back to Dashboard

Claims for Patent: RE29618

Title: Suppression of cardiac ventricular fibrillation and cardiac arrhythmias with bretylium tosylate
Abstract:A method for suppressing cardiac ventricular fibrillation and cardiac arrhythmias in animals, both human and otherwise, by administration of ortho-bromo benzyl ethyldimethylammonium p-toluene-sulfonate (bretylium tosylate). The drug may be administered prophylactically in the prevention of or in the treatment of ventricular fibrillation or cardiac arrhythmias.
Inventor(s): Bacaner; Marvin B. (Minneapolis, MN)
Assignee: The Regents of the University of Minnesota (Minneapolis, MN)
Application Number:05/781,654
Patent Claims: 1. A method for suppressing cardiac ventricular fibrillation and cardiac ventricular arrhythmias in living beings which comprises administering bretylium tosylate to said beings in a small but effective amount at least sufficient to restore sinus rhythm.

2. A method according to claim 1 further characterized in that said .[.salt.]. .Iadd.bretylium tosylate .Iaddend.is administered in amounts ranging from about 5 to 50 mg. per kg. of body weight.

3. A method according to claim 2 further characterized in that said .[.salt.]. .Iadd.bretylium tosylate .Iaddend.is administered in emergency treatment of .Iadd.ventricular fibrillation in living beings with .Iaddend.acute coronary occlusion intravenously in aqueous solution in amounts ranging from about 20 to 50 mg. per kg. of body weight accompanied by vigorous massage to hasten circulation of said drug to the heart and overcome resistance to electrical defibrillation.

4. A method according to claim 2 further characterized in that said .[.salt.]. .Iadd.bretylium tosylate .Iaddend.is administered in emergency treatment of .Iadd.ventricular fibrillation in living beings with .Iaddend.acute coronary insufficiency intravenously in aqueous solution in amounts ranging from about 20 to 50 mg. per kg. of body weight accompanied by vigorous massage to hasten circulation of said drug to the heart and overcome resistance to electrical defibrillation.

5. A method for suppressing cardiac ventricular fibrillation and cardiac ventricular arrhythmias in living beings which comprises administering to said beings a small but effective amount at least sufficient to restore sinus rhythm of bretylium tosylate in oral dosage at time intervals ranging from about every six to eight hours to once a day. .Iadd. 6. A method for suppressing cardiac ventricular fibrillation in living beings which comprises administering bretylium tosylate to said beings in a small but effective amount at least sufficient to restore sinus rhythm. .Iaddend. .Iadd. 7. A method according to claim 6 wherein said bretylium tosylate is administered intravenously. .Iaddend..Iadd. 8. A method for suppressing cardiac ventricular arrhythmias in living beings which comprises administering bretylium tosylate to said beings in a small but effective amount at least sufficient to restore sinus rhythm. .Iaddend..Iadd. 9. A method according to claim 8 wherein said arrhythmias are ventricular tachycardia. .Iaddend..Iadd. 10. A method according to claim 8 wherein said arrhythmias are ventricular premature beats. .Iaddend..Iadd. 11. A method according to claim 8 wherein said arrhythmias are ventricular extrasystoles. .Iaddend..Iadd. 12. A method according to claim 8 wherein said arrhythmias ae atrio-ventricular dissociation. .Iaddend..Iadd. 13. A method according to claim 8 wherein said bretylium tosylate is administered intravenously. .Iaddend.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc